Published in AIDS Weekly, May 20th, 2002
Trimeris of Durham, North Carolina, is codeveloping the drug, dubbed T-20, along with the U.S. subsidiary of the Swiss health care giant Roche Holding AG. Trimeris stock price rose $11.25 a share, or nearly 29%, to $50.50 at the close of trading April 18, 2002 on Nasdaq.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.